Search Results - "MEHEUS, Lydie"

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients by Verbaanderd, Ciska, Rooman, Ilse, Meheus, Lydie, Huys, Isabelle

“…Repurposing of medicines has gained a lot of interest from the research community in recent years as it could offer safe, timely, and affordable new treatment…”
Get full text

ReDO_DB: the repurposing drugs in oncology database by Pantziarka, Pan, Verbaanderd, Ciska, Sukhatme, Vidula, Rica Capistrano, I, Crispino, Sergio, Gyawali, Bishal, Rooman, Ilse, Van Nuffel, An Mt, Meheus, Lydie, Sukhatme, Vikas P, Bouche, Gauthier

“…Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity…”
Get full text

Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent by Pantziarka, Pan, Bouche, Gauthier, Sukhatme, Vidula, Meheus, Lydie, Rooman, Ilse, Sukhatme, Vikas P

“…Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of…”
Get full text

Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent by Pantziarka, Pan, Sukhatme, Vidula, Bouche, Gauthier, Meheus, Lydie, Sukhatme, Vikas P

“…Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological…”
Get full text

Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents by Pantziarka, Pan, Sukhatme, Vidula, Crispino, Sergio, Bouche, Gauthier, Meheus, Lydie, Sukhatme, Vikas P

“…Selective phosphodiesterase 5 inhibitors, including sildenafil, tadalafil and vardenafil, are widely-used in the treatment of erectile dysfunction and…”
Get full text

Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice by Selvanesan, Benson Chellakkan, Meena, Kiran, Beck, Amanda, Meheus, Lydie, Lara, Olaya, Rooman, Ilse, Gravekamp, Claudia

“…BackgroundTreatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor’s immune-suppressive stromal compartment. New…”
Get full text

Repurposing of Medicines in the EU: Launch of a Pilot Framework by Asker-Hagelberg, Charlotte, Boran, Tomas, Bouygues, Christelle, Eskola, Sini Marika, Helmle, Laszlo, Hernández, César, Houýez, François, Lee, Helen, Lingri, Dimitra D, Louette, Laurent, Meheus, Lydie, Penninckx, Wim, Stepniewska, Beata

“…Repurposing of authorised medicines has been under discussion for a long time. Drug repurposing is the process of identifying a new use for an existing…”
Get full text

Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections by DEPLA, Erik, VAN DER AA, Annegret, BABE, Lilia, DAHLBERG, Carol, MCKINNEY, Denise, SETTE, Alessandro, SOUTHWOOD, Scott, PHILIP, Ramilla, NEWMAN, Mark J, MEHEUS, Lydie, LIVINGSTON, Brian D, CRIMI, Claire, ALLOSERY, Koen, DE BRABANDERE, Veronique, KRAKOVER, Jonathan, MURTHY, Sidharta, HUANG, Manley, POWER, Scott

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 Contain Symmetrical Dimethylarginines, Which Form a Major B-cell Epitope for Anti-Sm Autoantibodies by Brahms, Hero, Raymackers, Jos, Union, Ann, de Keyser, Filip, Meheus, Lydie, Lührmann, Reinhard

“…The Sm proteins B/B′, D1, D2, D3, E, F, and G are components of the small nuclear ribonucleoproteins U1, U2, U4/U6, and U5 that are essential for the splicing…”
Get full text

Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as by Pantziarka, Pan, Sukhatme, Vidula, Crispino, Sergio, Bouche, Gauthier, Meheus, Lydie, Sukhatme, Vikas P

Get full text

Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus by GORDON, Patrick, KHAMASHTA, Munther A, HUGHES, Graham R. V, BUYON, Jill, ROSENTHAL, Eric, SIMPSON, John M, SHARLAND, Gurleen, BRUCATO, Antonio, FRANCESCHINI, Franco, DE BOSSCHERE, Katrien, MEHEUS, Lydie, MERONI, Pier Luigi

“…OBJECTIVE: Studies suggest that anti-52 kDa Ro antibodies are more sensitive and specific than anti-60 kDa Ro antibodies for neonatal lupus. However, these…”
Get full text

Ensuring completeness and timeliness of cancer treatment guidelines by Bouche, Gauthier, Meheus, Lydie

“…Timely and comprehensive updating of treatment guidelines remains a challenge and necessity in medical oncology. Herein we discuss our assessment of how trial…”
Get full text

Repurposing drugs in oncology: From candidate selection to clinical adoption by Pantziarka, Pan, Verbaanderd, Ciska, Huys, Isabelle, Bouche, Gauthier, Meheus, Lydie

“…Drug repurposing is a strategy that aims to develop novel cancer treatments through the reuse of existing medicines developed in other disease areas. Such a…”
Get full text

Journal retractions in oncology: a bibliometric study by Pantziarka, Pan, Meheus, Lydie

“…To investigate secular trends in article retractions in the oncology literature, particularly relating to cancer treatments and data available to patients. A…”
Get full text

Drug evidence watch: a process to the benefit of public health by Pantziarka, Pan, Roberts, Ian, Vandamme, Patricia, Meheus, Lydie, Bouche, Gauthier

“…[...]because only a marketing authorisation holder can file for label extension (a form of type II variation), this process requires the transfer of data from…”
Get full text

The European Union and personalised cancer medicine by Hickman, John A., Tannock, Ian F., Meheus, Lydie, Hutchinson, Lisa

“…Two recent policy documents by the European Union, ‘Europe's Beating Cancer Plan’ and its accompanying ‘Conquering Cancer: Mission Possible’ (CCMP), articulate…”
Get full text

Repurposing Drugs in Oncology: Next Steps by Verbaanderd, Ciska, Meheus, Lydie, Huys, Isabelle, Pantziarka, Pan

“…The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific…”
Get more information

Drug repurposing in oncology by Bouche, Gauthier, Gedye, Craig, Meheus, Lydie, Pantziarka, Pan

“…Ongoing trials are aiming at reversing resistance (eg, hydroxychloroquine with BRAF-MEK inhibition in BRAF-positive glioma), improving response (eg, nelfinavir…”
Get full text

Biased by design? Clinical trials and patient benefit in oncology by Pantziarka, Pan, Verbaanderd, Ciska, Meheus, Lydie

“…[...]a study that assessed all FDA approvals of novel drugs, across all areas of medicine in the period 2005-2012, reported wide disparities in pivotal trial…”
Get full text

Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al by Ugarte, Ana, Bouche, Gauthier, Meheus, Lydie

Get full text